Cough syrup deaths: Plea in Supreme Court for judicial commission inquiry

7 months ago 2
ARTICLE AD BOX
A presumption    of the Supreme Court of India. File

A presumption of the Supreme Court of India. File | Photo Credit: The Hindu

A petition was filed connected Tuesday (October 7, 2025) seeking an autarkic probe by a judicial committee oregon an adept committee to probe the cough syrup deaths which person claimed the lives of 14 children successful Madhya Pradesh.

The petition filed by advocator Vishal Tiwari has besides sought a transportation of the FIRs to the Central Bureau of Investigation (CBI). It has besides sought a broad enquiry into manufacture, regulation, investigating and organisation of contaminated cough syrups containing Diethylene Glycol, a toxic chemic utilized successful concern solvents, and suggestions for harmless manufacture of these medicines.

The plea urged the apex tribunal to prehend the contiguous banal of the now-banned Coldrif syrup and prohibition their merchantability oregon distribution. It said the banal indispensable beryllium tested for toxic clearance and verified astatine NABL laboratories.

A authorities doctor, who allegedly prescribed Coldrif, linked to the decease of respective children successful Madhya Pradesh, was arrested with the constabulary lodging a lawsuit against him and the Tamil Nadu-based manufacturer.

Uttar Pradesh bans Coldrif cough syrup aft 14 deaths successful Madhya Pradesh

The Madhya Pradesh Police has already formed a peculiar probe squad (SIT) to probe the case, portion the State Government suspended Dr. Praveen Soni, a paediatric specializer astatine the Civil Hospital successful the Parasia sub-division successful Chhindwara district, accused of prescribing the adulterated syrup — Coldrif — to galore of the deceased children astatine his backstage clinic.

An FIR was besides registered against Coldrif manufacturer, Sresan Pharmaceuticals, based successful Tamil Nadu’s Kancheepuram, nether Bharatiya Nyaya Sanhita (BNS) Sections 105 and 276, and Section 27A of the Drugs and Cosmetics Act.

Published - October 07, 2025 12:02 p.m. IST

Read Entire Article